Dr. Pamela Crilley on Imatinib and Second Generation TKIs Targeted Oncology 1:43 12 years ago 421 Далее Скачать
Dr. Pamela Crilley on Prescribing TKIs for the Treatment of CML Targeted Oncology 1:16 12 years ago 278 Далее Скачать
What are the newer options for patients who fail first- and second-generation TKI therapies? MediCom Oncology 1:30 8 years ago 44 Далее Скачать
Case 1: TKI Therapy and Sequencing Decisions in CP-CML Targeted Oncology 5:42 5 years ago 107 Далее Скачать
Dr. Kasper on Imatinib in Recist Progressive Desmoid Tumors OncLive 1:18 7 years ago 618 Далее Скачать
Outcomes of patients with CML-CP treated with ponatinib vs 2G-TKIs in the third-line setting VJHemOnc – Video Journal of Hematology & HemOnc 2:49 1 year ago 148 Далее Скачать
Keynote Session: Imatinib as a Paradigm of Targeted Cancer Therapies CPRITTexas 33:23 12 years ago 238 Далее Скачать
Frankly Speaking AML Sept 2019 Cancer Support Community Greater Philadelphia 1:00:31 5 years ago 16 Далее Скачать
Tyrosine Kinase Inhibitor toxicity in pediatric CML International CML Foundation 19:23 1 year ago 121 Далее Скачать
Should All Newly Diagnosed CP-CML Patients Start with a 2nd-generation TKI as Frontline Therapy? MedEdOTG 6:57 5 years ago 101 Далее Скачать
The impact of age and comorbidities on the outcomes of patients with CLL treated with BTK inhibitors VJHemOnc – Video Journal of Hematology & HemOnc 0:59 1 year ago 87 Далее Скачать
Ascertaining the mechanisms of resistance to KRASG12C inhibitors VJOncology 0:44 2 years ago 91 Далее Скачать
Discussing RA: Insights into Filgotinib and Tofacitinib in RA The Immune-Mediated Inflammatory Disease Forum 24:14 9 days ago 56 Далее Скачать
Dr. Michael Cohen, 2016 A-CURE Symposium on P2Y12 inhibitors effect on infarct size in an AMI cohort A-CURE Working Group 20:13 4 years ago 55 Далее Скачать
